PMID- 26191183
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20181113
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 8
IP  - 5
DP  - 2015
TI  - Unfractionated heparin attenuates intestinal injury in mouse model of sepsis by 
      inhibiting heparanase.
PG  - 4903-12
AB  - Intestinal injury is a key feature in sepsis. Heparanase, a heparin 
      sulfate-specific glucuronidase, mediates the onset of organ injury during early 
      sepsis. Heparin has the function to attenuate inflammation and injury induced by 
      multiple factors; however, whether unfractionated heparin (UFH) can attenuate the 
      intestinal injury induced by sepsis as well as the underlying mechanism is still 
      unknown. In the present study, the function of UFH in intestinal injury induced 
      by sepsis was explored. Results of our study showed that after CLP operation, the 
      inflammatory response and expression of heparanase were increased and NF-kappaB and 
      MAPK P38 signaling pathways were activated. However, pretreatment with UFH will 
      inhibit the expression and activation of heparanase, and reverse the activation 
      of NF-kappaB and MAPK P38 signaling pathways, thus attenuating inflammatory responses 
      induced by sepsis. These results suggest that UFH may be a promising therapeutic 
      drug for intestinal injury caused by sepsis.
FAU - Chen, Song
AU  - Chen S
AD  - Department of Critical Care Medicine, The First Affiliated Hospital of China 
      Medical University Shenyang 110001, People's Republic of China.
FAU - Zhang, Xiaojuan
AU  - Zhang X
AD  - Department of Critical Care Medicine, The First Affiliated Hospital of China 
      Medical University Shenyang 110001, People's Republic of China.
FAU - Sun, Yini
AU  - Sun Y
AD  - Department of Critical Care Medicine, The First Affiliated Hospital of China 
      Medical University Shenyang 110001, People's Republic of China.
FAU - Hu, Ziwei
AU  - Hu Z
AD  - Department of Critical Care Medicine, The First Affiliated Hospital of China 
      Medical University Shenyang 110001, People's Republic of China.
FAU - Lu, Siyu
AU  - Lu S
AD  - Department of Critical Care Medicine, The First Affiliated Hospital of China 
      Medical University Shenyang 110001, People's Republic of China.
FAU - Ma, Xiaochun
AU  - Ma X
AD  - Department of Critical Care Medicine, The First Affiliated Hospital of China 
      Medical University Shenyang 110001, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150501
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (NF-kappa B)
RN  - 9005-49-6 (Heparin)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - EC 3.2.1.- (heparanase)
RN  - EC 3.2.1.31 (Glucuronidase)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Cecum/microbiology/surgery
MH  - Cytoprotection
MH  - Disease Models, Animal
MH  - Enzyme Activation
MH  - Enzyme Inhibitors/*pharmacology
MH  - Glucuronidase/*antagonists & inhibitors/metabolism
MH  - Heparin/*pharmacology
MH  - Intestines/*drug effects/enzymology/pathology
MH  - Ligation
MH  - Male
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/metabolism
MH  - Punctures
MH  - Sepsis/*drug therapy/enzymology/microbiology/pathology
MH  - Signal Transduction/drug effects
MH  - Time Factors
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
PMC - PMC4503055
OTO - NOTNLM
OT  - MAPK
OT  - NF-kappaB
OT  - Unfractionated heparin
OT  - heparanase
OT  - intestinal injury
OT  - sepsis
EDAT- 2015/07/21 06:00
MHDA- 2016/04/19 06:00
PMCR- 2015/05/01
CRDT- 2015/07/21 06:00
PHST- 2015/01/22 00:00 [received]
PHST- 2015/03/21 00:00 [accepted]
PHST- 2015/07/21 06:00 [entrez]
PHST- 2015/07/21 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2015 May 1;8(5):4903-12. eCollection 2015.